Alyeska Investment Group
ELTX icon

Alyeska Investment Group’s Elicio Therapeutics ELTX Stock Holding History

Alyeska Investment Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,224
Closed -$420K – 710
2021
Q2 		$420K Sell
3,224
-1,776
-36% -$256K ﹤0.01% 655
2021
Q1 		$904K Buy
+5,000
New +$965K 0.01% 603

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Alyeska Investment Group's ELTX Position: Q3 2021 in Review

Alyeska Investment Group sold out of Elicio Therapeutics (ELTX) in Q3 2021, closing a stake of 3,224 shares — an estimated $420K sold.

Alyeska Investment Group first reported a position in ELTX in Q1 2021 and held it in 2 quarters. The position peaked at $904K in Q1 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q3 2021.

  • Alyeska Investment Group reported no remaining Elicio Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 3,224 Elicio Therapeutics shares in Q3 2021, an estimated $420K.
  • Alyeska Investment Group first reported a position in Elicio Therapeutics in Q1 2021 and held it in 2 quarters.
  • Alyeska Investment Group's Elicio Therapeutics position peaked at $904K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.